Loading
With longer follow-up, switching to camizestrant when an ESR1 mutation appeared in the blood kept its benefit and also lengthened control on the next treatment.
SERENA-6 tested ctDNA for ESR1 mutation every two to three months with Guardant360 CDx in patients on first-line aromatase inhibitor plus CDK4/6 inhibitor at 264 centres in 23 countries. From June 2021 to June 2024, 3,325 patients were screened, 3,256 had at least one test and 548 had a positive ESR1 test by screening closure; 315 were randomised to switch to camizestrant with the CDK4/6 inhibitor (157) or continue the aromatase inhibitor (158). At a median follow-up of 23.5 months, median progression-free survival was 16.8 months (95% CI 14.7 to 19.4) against 9.2 months (7.2 to 9.7), hazard ratio 0.45 (0.34 to 0.59), descriptive and consistent with the interim analysis. Median second progression-free survival was 25.7 months (20.4 to 30.3) against 19.1 months (16.8 to 21.0), hazard ratio 0.63 (0.46 to 0.86), p = 0.0037.
Acting on a resistant subclone found in blood keeps its benefit into the next line of treatment. It works where the clone carries a mutation that both marks it and chooses the drug.
Shares ESR1 mutation (ligand-binding domain, usually in ctDNA), ESR1 mutation, Estrogen receptor (ERα), The Lancet Oncology.
Shares ESR1 mutation (ligand-binding domain, usually in ctDNA), ESR1 mutation, SERENA-6, Estrogen receptor (ERα).
Shares ESR1 mutation, SERENA-6, Camizestrant, HR-positive / HER2-negative breast cancer.
Shares SERENA-6, Camizestrant, Estrogen receptor (ERα), Liquid biopsy (ctDNA).
Shares ESR1 mutation, SERENA-6, Camizestrant, Circulating tumour DNA (ctDNA).
Shares ESR1 mutation (ligand-binding domain, usually in ctDNA), SERENA-6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
Shares Camizestrant, AstraZeneca, HR-positive / HER2-negative breast cancer.
Shares Camizestrant, AstraZeneca, HR-positive / HER2-negative breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/